Companies reportedly affected included AI startups such as Moonshot AI and StepFun. Some reports also indicated that TikTok owner ByteDance faced similar restrictions involving secondary share sales to U.S. investors.
A later correction to one Reuters report clarified that regulators had “decided on” restrictions for ByteDance rather than directly instructing the company, highlighting the complexity of how such policies are implemented.
Taken together, these earlier reports suggested tighter oversight of U.S. capital entering strategic technology companies rather than a universal prohibition.
China’s response also aligns with its existing foreign‑investment regulatory system.
Under rules introduced in recent years, foreign investments that could affect national security must undergo a formal security review administered by authorities including the NDRC and the Ministry of Commerce. These measures allow regulators to examine investments in sectors considered sensitive or strategically important.
The framework means China can remain formally open to foreign capital while retaining the authority to review, restrict, or block deals involving technologies deemed critical to national interests.
The issue is unfolding amid growing geopolitical competition between the United States and China over advanced technologies such as semiconductors, artificial intelligence, and quantum computing.
Both governments have introduced policies affecting cross‑border investment in these sectors. Washington has implemented export controls and restrictions on certain U.S. investments in Chinese technology companies, citing national‑security concerns. Meanwhile, China has increasingly emphasized security screening for foreign investment in sensitive industries.
Against that backdrop, Beijing’s message appears designed to reassure markets that foreign investment remains welcome—while preserving regulatory discretion over deals involving strategic technologies.
China’s position can be summarized in three key points:
For investors and technology companies, the practical implication is that cross‑border funding is still possible—but it may face closer regulatory scrutiny when it involves sensitive technologies or major strategic firms.
Comments
0 comments